| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D P Birket. Clozapine compared with haloperidol for refractory schizophrenia. The New England journal of medicine. vol 338. issue 4. 1998-01-22. PMID:9441246. |
clozapine compared with haloperidol for refractory schizophrenia. |
1998-01-22 |
2023-08-12 |
Not clear |
| N R Schoole. New antipsychotic medications: strategies for evaluation and selected findings. Schizophrenia research. vol 27. issue 2-3. 1998-01-21. PMID:9416654. |
the unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the us food and drug administration for treatment of refractory schizophrenia. |
1998-01-21 |
2023-08-12 |
Not clear |
| A M Walker, L L Lanza, F Arellano, K J Rothma. Mortality in current and former users of clozapine. Epidemiology (Cambridge, Mass.). vol 8. issue 6. 1998-01-15. PMID:9345668. |
because it can induce agranulocytosis, however, clozapine is indicated only for schizophrenia that is not responsive to other therapies. |
1998-01-15 |
2023-08-12 |
Not clear |
| G Mas. Atypical neuroleptics in the treatment of early onset schizophrenia. Panminerva medica. vol 39. issue 3. 1998-01-13. PMID:9360425. |
the aim of this critical review is to describe clinical use of atypical neuroleptics clozapine and risperidone in children and adolescents with early-onset schizophrenia. |
1998-01-13 |
2023-08-12 |
Not clear |
| K E Wong, S A Chong, F Ngui, M Winslow, G S Devan, O K Leong, C H Cho. Initial experience with clozapine in Woodbridge Hospital. Singapore medical journal. vol 38. issue 8. 1998-01-08. PMID:9364887. |
this study was performed to evaluate the efficacy and side-effect profile of the atypical neuroleptic clozapine in local asian patients with treatment-resistant schizophrenia. |
1998-01-08 |
2023-08-12 |
Not clear |
| M Maes, E Bosmans, G Kenis, R De Jong, R S Smith, H Y Meltze. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophrenia research. vol 26. issue 2-3. 1998-01-06. PMID:9323354. |
in vivo immunomodulatory effects of clozapine in schizophrenia. |
1998-01-06 |
2023-08-12 |
human |
| J Martín, J C Gómez, E García-Bernardo, M Cuesta, E Alvarez, M Gurpegu. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. The Journal of clinical psychiatry. vol 58. issue 11. 1998-01-06. PMID:9413413. |
clozapine is currently the treatment of choice for neuroleptic-resistant schizophrenia. |
1998-01-06 |
2023-08-12 |
Not clear |
| Y Raoul, P Manesse, M Delag. [Quality of life of schizophrenic patients and clozapine]. L'Encephale. vol 23 Spec No 4. 1997-12-30. PMID:9417398. |
using a 'subjective quality of life profile' by gerin et al., the authors interviewed 22 patients presenting with 'recalcitrant schizophrenia' and treated with clozapine for more than 3 years. |
1997-12-30 |
2023-08-12 |
Not clear |
| O Gosselin, J M Ribeyre, J P Kah. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine]. L'Encephale. vol 23 Spec No 4. 1997-12-30. PMID:9417400. |
the discovery of clozapine in the mid-sixties and the demonstration of its clinical efficacy vis-à-vis recalcitrant schizophrenia contributed to the development of specific psychopharmacological research addressing the concept of atypical antipsychotics. |
1997-12-30 |
2023-08-12 |
Not clear |
| O Gosselin, J M Ribeyre, J P Kah. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine]. L'Encephale. vol 23 Spec No 4. 1997-12-30. PMID:9417400. |
first, identifying the action sites, in the brain, specific to clozapine and to conventional neuroleptics, in order to classify those drugs on the basis of the observed differences in pharmacoclinical profile (low incidence of neurological side effects, activity on schizophrenic deficiency symptoms, activity vis-à-vis certain forms of recalcitrant schizophrenia). |
1997-12-30 |
2023-08-12 |
Not clear |
| A S Brown, G Gewirtz, J Harkavy-Friedman, T Cooper, G Brébion, X F Amador, D Malaspina, J M Gorma. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 17. issue 5. 1997-12-22. PMID:9348547. |
effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. |
1997-12-22 |
2023-08-12 |
human |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
should clozapine be a first-line treatment for schizophrenia? |
1997-12-19 |
2023-08-12 |
Not clear |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
recent studies suggest that clozapine is more effective than typical neuroleptics for patients with treatment-resistant schizophrenia. |
1997-12-19 |
2023-08-12 |
Not clear |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
the hypothesis behind this article, however, is that clozapine may not only be more effective than typical neuroleptics for individuals with "first-episode" schizophrenia but may also lead to a better long-term course in such patients. |
1997-12-19 |
2023-08-12 |
Not clear |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
when examined in light of wyatt's recent proposal that each period of symptom exacerbation may lay the groundwork for further symptoms and for increasing syndrome severity, the data suggest that clozapine, despite its disturbing side-effect profile, should be studied in controlled double-blind clinical trials during patients' first episode of schizophrenia. |
1997-12-19 |
2023-08-12 |
Not clear |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
if such investigations show that clozapine is more effective than typical neuroleptics for patients with first-episode schizophrenia and results in a better long-term course, then its benefits and risk as a routine first-line treatment for schizophrenia can be considered. |
1997-12-19 |
2023-08-12 |
Not clear |
| R R Conley, R W Buchana. Evaluation of treatment-resistant schizophrenia. Schizophrenia bulletin. vol 23. issue 4. 1997-12-16. PMID:9366002. |
a systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of clozapine, risperidone, and olanzapine. |
1997-12-16 |
2023-08-12 |
Not clear |
| R Gutierrez-Esteinou, J A Greb. Risperidone: an analysis of the first three years in general use. International clinical psychopharmacology. vol 12 Suppl 4. 1997-12-10. PMID:9352340. |
in addition, a prospective comparison with risperidone and clozapine and a subanalysis of the north american trial of risperidone show that risperidone is effective in treatment-resistant schizophrenia. |
1997-12-10 |
2023-08-12 |
Not clear |
| M Herma. Clinical response to clozapine treatment of 11 chronic patients in a state psychiatric hospital. The Australian and New Zealand journal of mental health nursing. vol 6. issue 3. 1997-12-04. PMID:9384012. |
the aim of this study was to evaluate the clinical response to clozapine of 11 treatment-resistant patients with schizophrenia. |
1997-12-04 |
2023-08-12 |
Not clear |
| W Retz, M Rösler, L Sitzmann, T Becke. [Clozapine in treatment of neuropsychiatric diseases in the elderly]. Fortschritte der Neurologie-Psychiatrie. vol 65. issue 8. 1997-11-07. PMID:9378447. |
there are some studies and reports available about clozapine in the treatment of psychosis in patients suffering from dementia, schizophrenia and parkinson's disease, which are reported here. |
1997-11-07 |
2023-08-12 |
Not clear |